Conceptos Categóricos

BENEFICIOS DO TRATAMENTO FARMACOLOGICO NO TRATAMENTO DE MULHERES OBESAS

BENEFICIOS DO TRATAMENTO FARMACOLOGICO NO TRATAMENTO DE MULHERES OBESAS

(especial para SIIC © Derechos reservados)
A fluoxetina, associada a uma dieta apropriada, demonstrou ser um fármaco bem tolerado e eficaz na redução de parâmetros antropométricos e bioquímicos em mulheres obesas.
Autor:
Camila Guimarães
Columnista Experto de SIIC

Institución:
University of São Paulo


Artículos publicados por Camila Guimarães
Coautores
Leonardo Régis Leira Pereira* Edson Zangiacomi Martinez* Evandro José Cesarino* Regina H. C. Queiroz* 
University of São Paulo, São Paulo, Brasil*
Recepción del artículo
28 de Marzo, 2008
Aprobación
15 de Mayo, 2008
Primera edición
13 de Abril, 2009
Segunda edición, ampliada y corregida
19 de Agosto, 2009

Resumen
Este trabalho teve a finalidade de avaliar a eficácia clínica da fluoxetina (F), adjunta a uma dieta de 1 500 Kcal/dia, na redução de parâmetros antropométricos e bioquímicos em mulheres obesas. F (60 mg/dia), foi comparada ao Placebo (P) (n = 10) em 19 mulheres obesas, durante 90 dias de tratamento. O grupo F (n = 9) apresentou uma redução no IMC (-3.64 vs -0.45 kg/m2; p < 0.01) e circunferência abdominal (-12.3 vs -2.9 cm; p < 0.01). Observou-se ainda uma elevação dos níveis séricos de HDL-colesterol (+25.8%; p < 0.01), além de uma redução dos níveis plasmáticos médios de triglicérides (-28.3 % vs +18.7%; p < 0.01). As reações adversas mais comumente reportadas foram insônia, náuseas e sonolência. Concluímos que a fluoxetina, associada a uma dieta apropriada, demonstrou ser um fármaco bem tolerado e eficaz na redução de parâmetros antropométricos e bioquímicos em mulheres obesas.

Palabras clave
fluoxetina, obesidade, terapia farmacológica, reações adversas


Artículo completo

(castellano)
Extensión:  +/-5.18 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Abstract
Obesity is a chronic condition that has been reaching epidemic proportions worldwide. It is a risk factor for numerous medical disorders and excessive mortality. Long-term treatment, including pharmacotherapy, may be necessary for many obese patients. This study aimed to assess the potential benefits of fluoxetine (F), as an adjunct therapy to a 1 500 Kcal/day diet, in obese women. F (60 mg/day), was compared to placebo (P) in 19 obese females in a 90-day trial. F therapy (n = 9) resulted in a greater mean reduction in body weight (-9.24 vs -1.05 kg; p < 0.01), BMI (-3.64 vs -0.45 kg/m2, p < 0.01), and waist circumference (-12.3 vs -2.9 cm, p < 0.01) before and after the treatment, and also when compared with P group (n = 10). There was also an elevation of HDL-cholesterol before and after the treatment (p < 0.01; + 25.8%) and mean triglycerides levels was reduced before and after the treatment (p < 0.01; -28.3%), and also when compared with the P group. The drug was generally well tolerated and side effects most commonly reported were anorexia, insomnia, nausea and somnolence. We concluded that Fluoxetine may provide an effective and well tolerated possibility in reducing risk factors commonly associated with obesity.

Key words
fluoxetine, side effects, pharmacotherapy, obesity


Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Nutrición
Relacionadas: Endocrinología y Metabolismo, Farmacología, Medicina Farmacéutica, Medicina Interna, Salud Mental



Comprar este artículo
Extensión: 5.18 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Leonardo Régis Leira Pereira, University of São Paulo Faculty of Pharmaceutical Sciences of Ribeirão Preto Division of Clinical and Therapeutic Pharmacy, São Paulo, Brasil
Patrocinio y reconocimiento:
Agradecemos à Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) pelo apoio financeiro ao estudo.
Bibliografía del artículo
1. Marks JB. Advances in obesity treatment: clinical highlights from the NAASO 2003 Annual Meeting. Clin Diab 22:23-26, 2004.
2. Word Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity. Geneva, June 3-5, 1997. Geneva:WHO; 1998.
3. James P. Chair of the London-based International Obesity Task Force (IOTF). Monte Claro, 2003. Call for obesity review as overweight numbers reach 1.7 billion. [citado em 17 Mar 2006]. Disponível em: www.iotf.org/media/iotfmar17.htm.
4. Abate N. Obesity and cardiovascular disease: pathogenic role of the metabolic syndrome and therapeutic implications. Journal of Diabetes and its Complications 14:154-174, 2000.
5. Hill JO, Billington CJ. It's time to start treating obesity. Am J Cardiol 89:969-70, 2002.
6. Gokcel A, Gumurdulu Y, Karakose H, Ertorer EM, Tanaci N, Tutuncu NB et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diab Obes and Metab 4:49-55, 2002.
7. Seidell JC, Kahn HS, Williamson DF, Lissner L, Valdez R. Report from a centers for desease control and prevention workshop on use of adult anthropometry for public health and primary health care. Am J Clin Nutr 73:123-126, 2001.
8. Ellis KJ. Select body composition methods can be used in field studies. Phisiol Rev 80:649-680, 2000.
9. Atkinson RL. Use of drugs in the treatment of obesity. Annu Rev Nutr 17:383-403, 1997.
10. National Institutes of Health/National Heart Lung and Blood Institute, North American Association for the Study of Obesity (NHLBI/NAASO). Practical guide to the identification, evaluation, and treatment of overweight and obesity in adults. Bethesda 2000.
11. Gutiérrez A, Saracíbar G, Casis L, Echevarría E, Rodríguez VM, Macarulla MT, et al. Effects of fluoxetine administration on neuropeptide Y and orexins in obese Zucker rat hypothalamus. Obes Res 10:532-540, 2002.
12. Leibowitz SF, Weiss GF, Suh J. Medium hypothalamic nuclei mediate serotonin's inhibitory effect on feeding behaviour. Pharmac Biochem Behav 37:735-42, 1990.
13. Hsieh FY, Bloch DA, Larsen MD. A simple method of sample size calculation for linear and logistic regression. Statistics in Medicine 17(14):1623-34, 1998.
14. Stunkard AJMD. Current views on obesity. Am J Med 100(2):230-236, 1996.
15. Clinical Guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Am J Clin Nutr 68:899-917, 1998.
16. IDF. International Diabetes Federation [citado em Out 2005]. Disponível em: www.idf.org/webdata.docs/IDF_Metasyndrome_definition.pdf.
17. Rexrode KM, Carey VJ, Hennekens VH, Walters EE, Colditz GA, Stampfer MJ, et al. Abdominal obesity and coronary heart disease in women. JAMA 280:1843-8, 1998.
18. Blackburn G. Effect of degree of weight loss on health benefits. Obes Res 3:211S-216S, 1998.
19. Pedrinola F, Sztejnsznajd C, Lima N, Halpern A, Medeiros-Neto G. The addition of dexfenfluramine to fluoxetine in the treatment of obesity: a randomized clinical trial. Obes Res 4(6):549-554, 1996.
20. Daubresse JC, Kolanowski J, Krzentowski G, Kutnowski M, Scheen A, Van Gaal L. Usefullness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. Obes Res 4(4):391-396, 1996.
21. Duarte AC, Faillace GBD, Wadi MT, Pinheiro RL. Síndrome metabólica: semiologia, bioquímica e prescrição nutricional. Rio de Janeiro (RJ). Axcel Books do Brasil, 2005.
22. Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. J Clin Psychiatry 3:22-27, 2001.

 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618